PARSIPPANY, N.J., December 5, 2025 — Zoetis Inc. announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats, marking a significant milestone in veterinary pain management. Portela is a long-acting monoclonal antibody therapy designed to provide up to three months of OA pain relief with a single subcutaneous injection, offering veterinarians and pet owners a new, convenient option to address a common yet underdiagnosed chronic condition in feline patients.
Science Significance
From a scientific standpoint, Portela represents an important advancement in biologic therapies for companion animals. The therapy works by targeting nerve growth factor (NGF), a key mediator of osteoarthritis-related pain and inflammation. By binding to NGF at a distinct site, Portela interrupts pain signaling pathways without the need for daily oral medications. Clinical evidence from a nine-month European field trial demonstrated that Portela was effective and well tolerated, including in cats with early-stage chronic kidney disease, a population often limited in treatment options. These findings reinforce the growing role of monoclonal antibodies in veterinary medicine as precise, durable, and disease-specific interventions.
Regulatory Significance
The approval by Health Canada highlights a robust regulatory evaluation of safety, efficacy, and manufacturing quality for biologic veterinary medicines. Regulatory clearance was supported by controlled clinical data, real-world field studies, and pharmacovigilance assessments, reflecting increasing regulatory confidence in NGF-targeting therapies for chronic pain. With Portela also approved in the European Union, Zoetis demonstrates its ability to navigate multiple international regulatory frameworks, underscoring the maturity of veterinary biologics oversight and harmonization across major markets.
Business Significance
Advertisement
Commercially, the approval strengthens Zoetis’ position as a global leader in animal health innovation. Portela expands the company’s osteoarthritis pain portfolio, complementing existing products while addressing a large and underserved feline population. With up to 40% of cats showing clinical signs of OA, yet relatively low diagnosis rates, the market opportunity for long-acting pain therapies remains substantial. Zoetis plans to make Portela commercially available in Canada and the EU in 2026, supporting revenue growth through lifecycle innovation, geographic expansion, and biologics leadership in companion animal care.
Patients’ Significance
For feline patients and their caregivers, Portela offers a meaningful improvement in quality of life. Osteoarthritis pain affects not only mobility, but also sleep, behavior, social interaction, and cognition in cats. Because cats often mask pain and resist frequent medication, a once-every-three-month injection provides a practical and stress-reducing alternative. By delivering sustained pain relief, Portela enables cats to maintain comfort, activity, and daily function, while easing treatment burden for pet owners and caregivers.
Policy Significance
At a broader level, the approval reflects evolving animal health policy priorities that emphasize welfare, chronic pain recognition, and access to innovative therapies. As companion animals increasingly are viewed as integral family members, regulatory and professional frameworks are shifting toward earlier diagnosis and proactive pain management. Portela’s approval supports policies encouraging evidence-based veterinary care, improved education around feline OA, and the adoption of long-acting biologics to address chronic conditions in aging pet populations.
The Health Canada approval of Portela marks a notable advancement in veterinary medicine, combining scientific innovation, regulatory rigor, and patient-centered design. By introducing a long-acting NGF-targeting monoclonal antibody for feline osteoarthritis pain, Zoetis addresses a critical unmet need in companion animal health. As Portela enters the Canadian and European markets, it is poised to reshape standards of care for feline OA, reinforcing the growing impact of biologic therapies in veterinary practice.
Source: Zoetis Inc. press release
